Cargando…
Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
The incidence of ovarian cancer, which has had a poor prognosis, is increasing annually. Currently, the prognosis is expected to improve with the use of molecular-targeted drugs and immune checkpoint inhibitors as maintenance therapies after the first-line chemotherapy. The GOG218 and ICON7 studies...
Autores principales: | Shoji, Tadahiro, Sato, Chie, Tomabechi, Hidetoshi, Takatori, Eriko, Kaido, Yoshitaka, Nagasawa, Takayuki, Kagabu, Masahiro, Baba, Tsukasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155998/ https://www.ncbi.nlm.nih.gov/pubmed/34063455 http://dx.doi.org/10.3390/medicina57050501 |
Ejemplares similares
-
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021) -
Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study
por: Kagabu, Masahiro, et al.
Publicado: (2021) -
A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease
por: Shoji, Tadahiro, et al.
Publicado: (2019) -
Immunotherapy for Uterine Cervical Cancer
por: Kagabu, Masahiro, et al.
Publicado: (2019) -
A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023)